Cargando…
Probiotics in Inflammatory Bowel Disease: Are We Back to Square One?
Inflammatory bowel disease (IBD) is a chronic inflammatory condition of the alimentary tract whose incidence has been increasing over the past few years. Even though there is a complex interplay of several factors in the pathogenesis of IBD, a decrease in the diversity of intestinal microbiome is co...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7536108/ https://www.ncbi.nlm.nih.gov/pubmed/33042686 http://dx.doi.org/10.7759/cureus.10247 |
_version_ | 1783590493234397184 |
---|---|
author | Puvvada, Suvarna Rekha Luvsannyam, Enkhmaa Patel, Dhara Hassan, Zaira Hamid, Pousette |
author_facet | Puvvada, Suvarna Rekha Luvsannyam, Enkhmaa Patel, Dhara Hassan, Zaira Hamid, Pousette |
author_sort | Puvvada, Suvarna Rekha |
collection | PubMed |
description | Inflammatory bowel disease (IBD) is a chronic inflammatory condition of the alimentary tract whose incidence has been increasing over the past few years. Even though there is a complex interplay of several factors in the pathogenesis of IBD, a decrease in the diversity of intestinal microbiome is commonly found in patients. Extensive research is directed towards the alteration of this microbiome to improve the symptoms of IBD. Probiotics, prebiotics, antibiotics, and diet are studied in this regard extensively. Among them, probiotics have gained more interest as some of the studies showed them to be effective in decreasing gut inflammation in vitro and in vivo. Although there is no cure for IBD as of today, the available medications do decrease gut inflammation and help prolong remission and decrease relapse rates. But their side effects preclude their long-term use. Probiotics may be a ray of hope among IBD patients as they are apparently safe. This article reviews each of the available literature from the past 10 years to see if there is any certain role of probiotics in induction, maintenance of remission, prevention of relapse, and improvement in the quality of life in IBD patients. |
format | Online Article Text |
id | pubmed-7536108 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Cureus |
record_format | MEDLINE/PubMed |
spelling | pubmed-75361082020-10-08 Probiotics in Inflammatory Bowel Disease: Are We Back to Square One? Puvvada, Suvarna Rekha Luvsannyam, Enkhmaa Patel, Dhara Hassan, Zaira Hamid, Pousette Cureus Internal Medicine Inflammatory bowel disease (IBD) is a chronic inflammatory condition of the alimentary tract whose incidence has been increasing over the past few years. Even though there is a complex interplay of several factors in the pathogenesis of IBD, a decrease in the diversity of intestinal microbiome is commonly found in patients. Extensive research is directed towards the alteration of this microbiome to improve the symptoms of IBD. Probiotics, prebiotics, antibiotics, and diet are studied in this regard extensively. Among them, probiotics have gained more interest as some of the studies showed them to be effective in decreasing gut inflammation in vitro and in vivo. Although there is no cure for IBD as of today, the available medications do decrease gut inflammation and help prolong remission and decrease relapse rates. But their side effects preclude their long-term use. Probiotics may be a ray of hope among IBD patients as they are apparently safe. This article reviews each of the available literature from the past 10 years to see if there is any certain role of probiotics in induction, maintenance of remission, prevention of relapse, and improvement in the quality of life in IBD patients. Cureus 2020-09-04 /pmc/articles/PMC7536108/ /pubmed/33042686 http://dx.doi.org/10.7759/cureus.10247 Text en Copyright © 2020, Puvvada et al. http://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Internal Medicine Puvvada, Suvarna Rekha Luvsannyam, Enkhmaa Patel, Dhara Hassan, Zaira Hamid, Pousette Probiotics in Inflammatory Bowel Disease: Are We Back to Square One? |
title | Probiotics in Inflammatory Bowel Disease: Are We Back to Square One? |
title_full | Probiotics in Inflammatory Bowel Disease: Are We Back to Square One? |
title_fullStr | Probiotics in Inflammatory Bowel Disease: Are We Back to Square One? |
title_full_unstemmed | Probiotics in Inflammatory Bowel Disease: Are We Back to Square One? |
title_short | Probiotics in Inflammatory Bowel Disease: Are We Back to Square One? |
title_sort | probiotics in inflammatory bowel disease: are we back to square one? |
topic | Internal Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7536108/ https://www.ncbi.nlm.nih.gov/pubmed/33042686 http://dx.doi.org/10.7759/cureus.10247 |
work_keys_str_mv | AT puvvadasuvarnarekha probioticsininflammatoryboweldiseasearewebacktosquareone AT luvsannyamenkhmaa probioticsininflammatoryboweldiseasearewebacktosquareone AT pateldhara probioticsininflammatoryboweldiseasearewebacktosquareone AT hassanzaira probioticsininflammatoryboweldiseasearewebacktosquareone AT hamidpousette probioticsininflammatoryboweldiseasearewebacktosquareone |